



The Life Raft

GROUP



Research • Patient Support & Education • Advocacy

Imatinib Generics Access Survey


September 13 – October 3, 2016

200 Responses


 81 (40.5%) **Male** |
  107 (53.5%) **Female** |
 No Response 11 (5.5%)

2 (1 %)	Ages 18-34	14 (7%)	High school or less
99 (49.5%)	Ages 35-64	32 (16%)	Some college
88 (44%)	Ages 65+	68 (34%)	College Graduate
11 (5.5%)	No Response	73 (36.5%)	Graduate School
		13 (6.5%)	No Response

Are you currently on Generic Imatinib?




If currently on Generic Imatinib, were you on the brand drug, Gleevec, prior to switching?




If you have switched to a generic version, what was your main reason for switching?


34 out of the 42 were previously on brand drug (Gleevec)




If you are currently on the generic, who is the manufacturer?



If you have NOT switched to the generic and you have been given the option to, would you switch towards the generic?




Entity which covers Gleevec or its generic version




Other includes: PSI, VA, No Insurance, Novartis, UK NHS (International)


Have you encountered any issues in insurance coverage




Out of Pocket costs for GIST medication



How informed are you about generic imatinib?




Are you familiar with your state's law of Drug Product Selection or "Dispense as Written" Law



Primary Source of Information

The LRG ranked number 1 as the primary source of information for patients regarding generic imatinib.




Experience Navigating Patient Assistance Programs

NOTE:

33 responders have reported reaching out to Novartis for assistance
(Co-Pay Card, GIPAP, NPAF)

28 responders reported reaching out to other programs

139 responders are not utilizing assistance programs



Thank You to all the patients and
caregivers who participated in this
survey!